Evidence map›Paper›PMID 41801437›Full record

ArticleClinical research in cardiology : official journal of the German Cardiac Society2026

Impact of SGLT2 inhibitors in patients with Fabry disease.

Malte Lenders, Sima Canaan-Kühl, Christine Kurschat, Albina Nowak, Constantin Gatterer, Victoria Sokalski, Fabian Braun, Markus Cybulla, Gere Sunder-Plassmann, Peter Nordbeck and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Malte LendersDepartment of Internal Medicine D, and Interdisciplinary Fabry Center (IFAZ), University Hospital Muenster, Albert-Schweitzer-Campus 1, Muenster, D-48149, Germany.ORCID http://orcid.org/0000-0001-8409-2886
Sima Canaan-KühlDepartment of Medicine, Division of Nephrology, Center for Rare Kidney Diseases (CeRKiD), Universitätsmedizin Campus Mitte, Charité, Berlin, Germany.
Christine KurschatDepartment II of Internal Medicine, Center for Molecular Medicine Cologne and Center for Rare Diseases, University of Cologne, Cologne, Germany.
Albina NowakDepartment of Endocrinology and Clinical Nutrition, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Constantin GattererDivision of Cardiology, Department of Medicine II, Medical University of Vienna, Vienna, Austria.
Victoria SokalskiDepartment of Internal Medicine I, Comprehensive Heart Failure Center, Fabry Center for Interdisciplinary Therapy (FAZIT), University of Wuerzburg, Würzburg, Germany.
Fabian BraunIII. Department of Medicine and Hamburg Center for Kidney Health, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Markus CybullaDepartment of Nephrology and Rheumatology, Nephrologicum-MGL MVZ, Muellheim, Germany.
Gere Sunder-PlassmannDivision of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Peter NordbeckDepartment of Internal Medicine I, Comprehensive Heart Failure Center, Fabry Center for Interdisciplinary Therapy (FAZIT), University of Wuerzburg, Würzburg, Germany.
Christoph WannerDepartment of Internal Medicine I, Comprehensive Heart Failure Center, Fabry Center for Interdisciplinary Therapy (FAZIT), University of Wuerzburg, Würzburg, Germany.
Eva BrandDepartment of Internal Medicine D, and Interdisciplinary Fabry Center (IFAZ), University Hospital Muenster, Albert-Schweitzer-Campus 1, Muenster, D-48149, Germany. Eva.Brand@ukmuenster.de.

Funding

Deutsches Zentrum für Luft- und Raumfahrt 01EO2106
6 · The paper itself

Abstract

aimsFabry disease (FD) is a multisystemic disease affecting the heart and the kidneys of affected patients. In addition to FD-specific treatment, patients require concomitant medication for cardio- and nephroprotection. Sodium-dependent glucose transporter 2 inhibitors (SGLT2i) are recommended for patients with heart failure and/or kidney disease, but efficacy data for FD are scarce. METHODS AND

resultsIn this multicenter study (n = 8), the effects of SGLT2i therapy after 12 months of treatment in 48 patients (12 females) on FD-specific therapy were examined. Patients were retrospectively analyzed at three time points (before SGLT2i: T

conclusionTreatment with SGLT2i of FD patients was safe and patients presented with stable disease courses. Especially males with reduced LVEF might benefit from SGLT2i treatment.

Indexed as

AlbuminuriaDisease progressioneGFREjection fractionEnzyme replacement therapyHFrEFMigalastatSGLT2 inhibitor

Identifiers

PMID41801437

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.